

## **Base Pair Biotechnologies Completes \$3.2 Million Series A-3 Financing Round and Opens New Facility**

*Accelerates growth in cell analysis, new technology and market development*

November 28, 2017 10:40 AM Eastern Standard Time

PEARLAND, Texas--(Business Wire)--Base Pair Biotechnologies, Inc., The Aptamer Discovery Company™, today announced the completion of its \$3.2 Million Series A-3 financing round and the opening of its new 5,000 square foot laboratory and office facility in Pearland, TX, a Houston suburb. Toronto-based Eventi Capital Partners Inc. and Base Pair Canada led the round, with participation from earlier investors Houston-based BioTex, Inc. and Ashok Gowda, BioTex's President & CEO, one of Base Pair's founders.

Base Pair combines a highly customized aptamer discovery approach with a patented multiplexing technology, bringing together DNA barcoding and next generation sequencing to enable simultaneous identification of aptamers that bind up to 30 different targets. Aptamers are small, synthetic RNA or DNA molecules that fold into unique shapes, which enable them to selectively and tightly bind to molecular, viral or cellular targets. Base Pair will use the investment to acquire new lab instruments and other technology that will allow the company to expand its cellular and molecular analysis capabilities, enabling improved methods for finding aptamers that bind targets on and in live cells. The funding will also be used to expand the team, providing additional technical capability and enhancing geographical reach.

"Aptamers provide solutions to customer problems that are hard, if not impossible to solve with antibodies," said Vicki Singer, President and CEO of Base Pair, "especially for small molecule targets, toxic molecules, and targets with low antigenicity. Base Pair's unique value proposition lies in the scientific strength and creativity of its team, which includes cell biologists, molecular and microbiologists and biochemists, with decades of experience."

"The focus on problem-solving rather than aptamer generation really sets Base Pair apart," said Scott Bryan, Managing Partner, Eventi. "We believe that the company is poised to rapidly expand in multiple market sectors and are pleased to have the opportunity to participate." Eventi is a growth capital investment group founded in 2001, specializing in software-as-a-service, internet infrastructure services, medical devices and life sciences

"Base Pair is delivering great results with tremendous growth potential that we're excited to continue to support," said Michele Gowda of Base Pair Canada.

### **About Base Pair Biotechnologies**

Base Pair Biotechnologies is a privately held aptamer discovery and development company, spun out of Biotex, Inc. in 2012. The company provides custom aptamer discovery and development services, as well as offering a small line of catalog aptamers, and has a significant and growing intellectual property portfolio in the aptamer space. Base Pair serves a diverse range of customer segments, including pharma and biopharma, diagnostics, environmental testing, and veterinary medicine.

### **Media Contacts**

*Base Pair Biotechnologies*

Vicki Singer, Ph.D., President & CEO  
8619 Broadway Street, Suite 100  
Pearland, TX 77584  
UNITED STATES  
832-230-5518  
vicki.singer@basepairbio.com

*Eventi Capital Partners*

Scott Bryan  
250 Yonge Street, Unit 1602  
M5G 1B1  
Toronto, Ontario  
CANADA  
416-927-8887  
scott.bryan@eventi.com